{
    "body": "What is the major adverse effect of adriamycin(doxorubicin)?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21295102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3947104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15114698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3459397", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3461747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12445862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7325994"
    ], 
    "ideal_answer": [
        "Cardiac toxicity is a major adverse effect caused by doxorubicin (DOX) therapy  ", 
        "Cardiac toxicity is a major adverse effect caused by doxorubicin (DOX) therapy. In spite of the routine use of this drug its major adverse effect, the dose-dependent cardiotoxicity, cannot be prevented yet. Cardiotoxicity is a major adverse effect of the anthracycline antibiotics and can be acute or chronic."
    ], 
    "exact_answer": [
        "Cardiotoxicity", 
        "Cardiac toxicity"
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4269440", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004317"
    ], 
    "type": "factoid", 
    "id": "53551206a0726bee57000001", 
    "snippets": [
        {
            "offsetInBeginSection": 972, 
            "offsetInEndSection": 1158, 
            "text": "It remains to be seen whether inhibition by adriamycin of these systems is related to the severe cardiotoxicity, the major adverse effect of the drug that limits its clinical usefulness.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7325994", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 961, 
            "offsetInEndSection": 1058, 
            "text": "Leukocytopenia was the major adverse effect among patients undergoing systemic THP administration", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3947104", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 536, 
            "offsetInEndSection": 589, 
            "text": "The major adverse effect was bone-marrow suppression;", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3459397", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 813, 
            "offsetInEndSection": 866, 
            "text": "The major adverse effect was bone marrow suppression;", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3461747", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 644, 
            "offsetInEndSection": 746, 
            "text": "Cardiotoxicity is a major adverse effect of the anthracycline antibiotics and can be acute or chronic;", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 864, 
            "offsetInEndSection": 1034, 
            "text": "chronic cardiotoxicity represents a serious adverse effect that may be lethal due to the development of irreversible, cumulative dose-dependent, congestive cardiomyopathy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 380, 
            "offsetInEndSection": 642, 
            "text": "Myelosuppression, predominantly neutropenia and leucopenia, is the dose-limiting toxicity; in addition to this, mucositis, nausea, vomiting and alopecia are frequent, whereas hepatopathy, characterised by elevated bilirubin concentrations, occurs less frequently", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 115, 
            "offsetInEndSection": 240, 
            "text": "In spite of the routine use of this drug its major adverse effect, the dose-dependent cardiotoxicity, cannot be prevented yet", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445862", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 389, 
            "offsetInEndSection": 434, 
            "text": "The major adverse effect was myelosuppression", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15114698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 78, 
            "text": "Cardiac toxicity is a major adverse effect caused by doxorubicin (DOX) therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 107, 
            "text": "Antioxidative and cardioprotective effects of Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 55, 
            "offsetInEndSection": 164, 
            "text": "The major adverse effect of DOX treatment in cancer patients is the onset of cardiomyopathy and heart failure", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21295102", 
            "endSection": "abstract"
        }
    ]
}